ZFTRAF1

Summary

ZFTRAF1 (zinc finger TRAF-type and ring finger containing 1, HGNC:17806) is a protein-coding gene on chromosome 8q24.3, encoding Zinc finger TRAF-type-containing protein 1 (P0DTL6).

Predicted to enable zinc ion binding activity. Predicted to be located in nuclear envelope and perinuclear region of cytoplasm. Predicted to be active in nucleus.

Source: NCBI Gene 50626 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder (Limited, GenCC) — +1 more curated relationship
• GWAS associations: 10
• Clinical variants (ClinVar): 1 total
• MANE Select transcript: NM_001330618

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:17806
Approved symbol	ZFTRAF1
Name	zinc finger TRAF-type and ring finger containing 1
Location	8q24.3
Locus type	gene with protein product
Status	Approved
Aliases	CHRP, KIAA0496, MGC13010
Ensembl gene	ENSG00000187954
Ensembl biotype	protein_coding
OMIM	616635
Entrez	50626

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 retained_intron, 2 protein_coding

ENST00000528558, ENST00000528663, ENST00000530374, ENST00000533173, ENST00000959494

RefSeq mRNA: 3 — MANE Select: NM_001330618 NM_001330618, NM_001408047, NM_001408048

CCDS: CCDS83335

Canonical transcript exons

ENST00000530374 — 4 exons

Exon	Start	End
ENSE00002163517	144462283	144462871
ENSE00004474034	144449582	144450770
ENSE00004474158	144453222	144453460
ENSE00004474165	144452359	144452570

Expression profiles

Bgee: expression breadth ubiquitous, 260 present calls, max score 97.33.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 25.7729 / max 180.2029, expressed in 1815 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
95684	10.7204	1796
95685	10.6034	1733
95686	4.4491	1585

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	97.33	gold quality
apex of heart	UBERON:0002098	97.25	gold quality
cerebellar hemisphere	UBERON:0002245	97.06	gold quality
cerebellar cortex	UBERON:0002129	96.91	gold quality
left testis	UBERON:0004533	96.74	gold quality
right testis	UBERON:0004534	96.69	gold quality
adenohypophysis	UBERON:0002196	96.66	gold quality
right frontal lobe	UBERON:0002810	96.15	gold quality
right adrenal gland	UBERON:0001233	96.05	gold quality
right adrenal gland cortex	UBERON:0035827	95.87	gold quality
left adrenal gland cortex	UBERON:0035825	95.85	gold quality
lower esophagus mucosa	UBERON:0035834	95.78	gold quality
pituitary gland	UBERON:0000007	95.69	gold quality
body of pancreas	UBERON:0001150	95.65	gold quality
right coronary artery	UBERON:0001625	95.56	gold quality
left adrenal gland	UBERON:0001234	95.51	gold quality
endocervix	UBERON:0000458	95.30	gold quality
cerebellum	UBERON:0002037	95.16	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.08	gold quality
adrenal cortex	UBERON:0001235	94.98	gold quality
cingulate cortex	UBERON:0003027	94.98	gold quality
right ovary	UBERON:0002118	94.95	gold quality
anterior cingulate cortex	UBERON:0009835	94.93	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.91	gold quality
body of uterus	UBERON:0009853	94.90	gold quality
right lobe of thyroid gland	UBERON:0001119	94.88	gold quality
nucleus accumbens	UBERON:0001882	94.87	gold quality
mucosa of transverse colon	UBERON:0004991	94.85	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.84	gold quality
body of stomach	UBERON:0001161	94.83	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.19

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

16 targeting ZFTRAF1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-3191-5P	99.24	66.52	1722
HSA-MIR-3074-5P	98.82	66.56	1414
HSA-MIR-222-5P	98.75	69.17	1242
HSA-MIR-3944-5P	98.50	67.55	997
HSA-MIR-1910-3P	98.44	67.51	1695
HSA-MIR-6511A-5P	98.13	67.47	1770
HSA-MIR-3663-5P	97.01	64.84	713
HSA-MIR-601	95.98	67.59	421
HSA-MIR-1204	89.50	65.56	109

Literature-anchored findings (GeneRIF, showing 2)

• High CYHR1 expression is associated with Esophageal Squamous Cell Carcinoma. (PMID:26676980)
• Biallelic loss-of-function variants of ZFTRAF1 cause neurodevelopmental disorder with microcephaly and hypotonia. (PMID:38641995)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	zftraf1	ENSDARG00000061057
mus_musculus	Gm57852	ENSMUSG00000121583
rattus_norvegicus	Tmem276-zftraf1	ENSRNOG00000014811
drosophila_melanogaster	CG32486	FBGN0266918

Protein

Protein identifiers

Zinc finger TRAF-type-containing protein 1 — P0DTL6 (reviewed: P0DTL6)

Alternative names: Cysteine and histidine-rich protein 1

All UniProt accessions (1): P0DTL6

UniProt curated annotations — full annotation on UniProt →

Subunit / interactions. Interacts with LGALS3.

Subcellular location. Cytoplasm. Perinuclear region.

Similarity. Belongs to the ZFTRAF1 family.

Isoforms (4)

UniProt ID	Names	Canonical?
P0DTL6-5	5	yes
P0DTL6-1	1
P0DTL6-2	2
P0DTL6-4	4

RefSeq proteins (3): NP_001317547, NP_001394976, NP_001394977 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001293	Znf_TRAF	Domain
IPR001841	Znf_RING	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR039338	ZFTRAF1	Family
IPR049548	Sina-like_RING	Domain

Pfam: PF21362

UniProt features (9 total): splice variant 4, zinc finger region 2, chain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P0DTL6-F1	82.71	0.68

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 86 (showing top): GSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_DN, TSENG_IRS1_TARGETS_UP, TGCGCANK_UNKNOWN, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, CASTELLANO_NRAS_TARGETS_DN, BLALOCK_ALZHEIMERS_DISEASE_UP, MARTINEZ_RESPONSE_TO_TRABECTEDIN_DN, SCHLOSSER_SERUM_RESPONSE_AUGMENTED_BY_MYC, BERENJENO_TRANSFORMED_BY_RHOA_UP, PARENT_MTOR_SIGNALING_UP, GOCC_NUCLEAR_ENVELOPE, NUYTTEN_EZH2_TARGETS_DN, NIKOLSKY_BREAST_CANCER_8Q23_Q24_AMPLICON, SWEET_LUNG_CANCER_KRAS_UP

GO Biological Process (0):

GO Molecular Function (3): zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (4): nucleus (GO:0005634), nuclear envelope (GO:0005635), perinuclear region of cytoplasm (GO:0048471), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	2
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nucleus	1
endomembrane system	1
organelle envelope	1
cytoplasm	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

34 interactions, top by confidence:

A	B	Type	Score
UBE2K	ZFTRAF1	psi-mi:“MI:0914”(association)	0.620
UBE2K	ZFTRAF1	psi-mi:“MI:0915”(physical association)	0.620
HAO2	EIF4G3	psi-mi:“MI:0914”(association)	0.530
TNFAIP3	UBB	psi-mi:“MI:0914”(association)	0.530
VPS36	UBB	psi-mi:“MI:0914”(association)	0.530
DEGS1	ZFTRAF1	psi-mi:“MI:0915”(physical association)	0.400
Ube2k		psi-mi:“MI:0914”(association)	0.350
Ube2k	ZFTRAF1	psi-mi:“MI:0914”(association)	0.350
FAM189B	KLRG2	psi-mi:“MI:0914”(association)	0.350
SLC45A2	TMEM63A	psi-mi:“MI:0914”(association)	0.350
SDC1	ARVCF	psi-mi:“MI:0914”(association)	0.350
DNAJB2	UBB	psi-mi:“MI:0914”(association)	0.350
LITAF	SDCBP	psi-mi:“MI:0914”(association)	0.350
EPN3	MID1	psi-mi:“MI:0914”(association)	0.350
RABGEF1	GAK	psi-mi:“MI:0914”(association)	0.350
PLXNB2	C2CD4B	psi-mi:“MI:0914”(association)	0.350
LRRC73	THAP12	psi-mi:“MI:0914”(association)	0.350
TLCD5	TOM1L1	psi-mi:“MI:0914”(association)	0.350
RNF5	ZFTRAF1	psi-mi:“MI:0914”(association)	0.350
PNMA6A	ZFTRAF1	psi-mi:“MI:0914”(association)	0.350
LRRC73	SLC27A2	psi-mi:“MI:0914”(association)	0.350
STX5	ZFTRAF1	psi-mi:“MI:0914”(association)	0.350
IL23R	ZFTRAF1	psi-mi:“MI:0914”(association)	0.350

ESM2 similar proteins: A5WW08, A7XUJ6, B5DF45, B6CJY4, B6CJY5, O00463, O15344, O70583, P0DTL6, P0DW87, P0DW89, P39429, P70191, P70196, P82457, P82458, Q08CH8, Q12933, Q13114, Q28DL4, Q29RQ5, Q2TAD9, Q3KPU8, Q3MV19, Q3U9F6, Q3ZCC3, Q5FWP4, Q5R4L1, Q60803, Q61382, Q6DJN2, Q6GNX1, Q6IWL4, Q6J1I7, Q6P256, Q80WG7, Q8N2W9, Q91ZY8, Q95KF1, Q96A37

Diamond homologs: P0DTL6, P0DW87, P0DW89, P0DW91, P93748, Q08CH8, Q2TAD9, Q6GNX1, Q9M2P4, Q9VZV5, A8X679, O43255, P21461, P29304, P61092, P61093, Q06985, Q06986, Q10L91, Q7SYL3, Q7XA77, Q7ZVG6, Q84JL3, Q84K34, Q86MW9, Q8I147, Q8IUQ4, Q8R4T2, Q8S3N1, Q8T3Y0, Q920M9, Q93WE4, Q965X6, Q9C6H2, Q9C6H3, Q9C6H4, Q9C9M0, Q9FKD5, Q9FKD6, Q9FKD7

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	1
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

947 predictions. Top by Δscore:

Variant	Effect	Δscore
8:144450766:GACCT:G	acceptor_gain	1.0000
8:144450767:ACCT:A	acceptor_gain	1.0000
8:144450768:CCTC:C	acceptor_gain	1.0000
8:144450769:CT:C	acceptor_gain	1.0000
8:144450770:TC:T	acceptor_loss	1.0000
8:144450771:C:CC	acceptor_gain	1.0000
8:144450771:CT:C	acceptor_loss	1.0000
8:144450773:G:C	acceptor_gain	1.0000
8:144450773:G:GC	acceptor_gain	1.0000
8:144450780:C:CT	acceptor_gain	1.0000
8:144450781:A:T	acceptor_gain	1.0000
8:144450784:C:CT	acceptor_gain	1.0000
8:144450785:A:T	acceptor_gain	1.0000
8:144450970:C:CT	acceptor_gain	1.0000
8:144452357:A:AC	donor_gain	1.0000
8:144452357:A:C	donor_loss	1.0000
8:144452358:C:CC	donor_gain	1.0000
8:144452566:TTACC:T	acceptor_gain	1.0000
8:144452568:ACCC:A	acceptor_loss	1.0000
8:144452569:CC:C	acceptor_gain	1.0000
8:144452570:CC:C	acceptor_gain	1.0000
8:144452570:CCTGG:C	acceptor_loss	1.0000
8:144452571:C:CC	acceptor_gain	1.0000
8:144453217:GTTA:G	donor_loss	1.0000
8:144453218:TTAC:T	donor_loss	1.0000
8:144453219:TACCT:T	donor_loss	1.0000
8:144453220:AC:A	donor_loss	1.0000
8:144453221:C:G	donor_loss	1.0000
8:144453234:T:TA	donor_gain	1.0000
8:144450790:C:CT	acceptor_gain	0.9900

AlphaMissense

2619 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:144450429:C:G	A347P	1.000
8:144450431:A:G	L346P	1.000
8:144450431:A:T	L346Q	1.000
8:144450434:A:G	L345P	1.000
8:144450563:A:G	L302P	1.000
8:144450627:G:T	R281S	1.000
8:144450665:A:T	V268D	1.000
8:144450671:G:T	A266D	1.000
8:144450672:C:G	A266P	1.000
8:144450677:A:G	L264P	1.000
8:144450684:A:G	W262R	1.000
8:144450684:A:T	W262R	1.000
8:144450720:A:C	Y250D	1.000
8:144450736:G:C	F244L	1.000
8:144450736:G:T	F244L	1.000
8:144450737:A:G	F244S	1.000
8:144450738:A:G	F244L	1.000
8:144450749:C:G	R240P	1.000
8:144450750:G:T	R240S	1.000
8:144450753:A:C	Y239D	1.000
8:144452491:A:G	C189R	1.000
8:144452531:C:A	W175C	1.000
8:144452531:C:G	W175C	1.000
8:144452533:A:G	W175R	1.000
8:144452533:A:T	W175R	1.000
8:144452538:C:G	C173S	1.000
8:144452539:A:G	C173R	1.000
8:144452539:A:T	C173S	1.000
8:144452559:C:G	C166S	1.000
8:144452560:A:G	C166R	1.000

dbSNP variants (sampled 300 via entrez): RS1000026052 (8:144459645 G>A), RS1000209806 (8:144462357 T>C), RS1000336116 (8:144462617 G>A), RS1000379339 (8:144455239 C>T), RS1000452034 (8:144462340 G>A,C), RS1000574372 (8:144461753 A>C), RS1000759903 (8:144455272 G>A), RS1000859411 (8:144449839 T>C), RS1000988999 (8:144461596 C>G), RS1001105885 (8:144454091 G>A), RS1001120547 (8:144450037 G>A,C), RS1001195114 (8:144459601 C>G), RS1001196453 (8:144463603 A>C,G), RS1001206207 (8:144463374 C>G,T), RS1001220384 (8:144451437 G>A)

Disease associations

OMIM: gene MIM:616635 | disease phenotypes: MIM:249500

GenCC curated gene-disease

Disease	Classification	Inheritance
complex neurodevelopmental disorder	Limited	Autosomal recessive
neurodevelopmental disorder	Limited	Autosomal recessive

Mondo (3): autosomal recessive non-syndromic intellectual disability (MONDO:0019502), complex neurodevelopmental disorder (MONDO:0100038), neurodevelopmental disorder (MONDO:0700092)

Orphanet (1): Autosomal recessive non-syndromic intellectual disability (Orphanet:88616)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

10 associations (top):

Study	Trait	p-value
GCST002598_30	Educational attainment	9.000000e-06
GCST003795_8	Age at first birth	6.000000e-07
GCST006045_10	Age at first birth	6.000000e-09
GCST006269_728	General cognitive ability	1.000000e-08
GCST006879_12	Blood metabolite levels	4.000000e-10
GCST006879_13	Blood metabolite levels	2.000000e-09
GCST006879_14	Blood metabolite levels	2.000000e-11
GCST006879_5	Blood metabolite levels	2.000000e-12
GCST008595_130	Cognitive ability, years of educational attainment or schizophrenia (pleiotropy)	1.000000e-09
GCST90000050_61	Age at first birth	6.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004784	self reported educational attainment
EFO:0009101	age at first birth measurement
EFO:0004337	intelligence

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, affects cotreatment, increases expression	2
Nickel	decreases expression	2
aristolochic acid I	increases expression	1
testosterone enanthate	affects expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
K 7174	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Fulvestrant	increases methylation	1
Acetaminophen	increases expression	1
Air Pollutants	decreases expression	1
Air Pollutants, Occupational	decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Cadmium	increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	decreases expression	1
Ethyl Methanesulfonate	increases expression	1
Indomethacin	affects cotreatment, increases expression	1
Methyl Methanesulfonate	increases expression	1
Plant Extracts	increases expression, affects cotreatment	1
Selenomethionine	affects expression	1
Tretinoin	increases expression	1
Valproic Acid	increases methylation	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Copper Sulfate	decreases expression	1
Vitamin K 3	affects expression	1

Clinical trials (associated diseases)

204 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism